Company Profile
Innoviva Stock Price, News & Analysis
- Ticker:
- INVA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
21.11 USD (+2.93%)
Close
Last updated: August 6, 2026
1.58B USD
Market cap
Why the stock is moving
Following the latest company update, “Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress”, INVA closed up 2.93% at $21.11 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Diversified Biopharmaceutical Model
Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies.
Respiratory Royalties
The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support investment in additional healthcare assets.
Innoviva Specialty Therapeutics
The IST portfolio includes GIAPREZA for distributive shock, XACDURO for hospital-acquired bacterial pneumonia, XERAVA for complicated intra-abdominal infections and ZEVTERA, an advanced-generation cephalosporin.
NUZOLVENCE
NUZOLVENCE is an oral antibiotic approved for uncomplicated urogenital gonorrhea in adults and eligible adolescents, adding a differentiated infectious-disease product to IST.
Future catalysts
U.S. commercial availability of NUZOLVENCE in the second half of 2026.
Recent news
- 01
- 02
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Source: Innoviva
- 03
- 04
Innoviva to Participate in Upcoming Investor Conferences
Source: Innoviva
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Innoviva (INVA)?
Innoviva (INVA) most recently closed at 21.11 USD, a +2.93% move versus the previous session.
What is the market cap of Innoviva (INVA)?
Innoviva currently has a market capitalization of 1.58B USD on BioPharmSignal.
What does Innoviva do?
Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support investment in additional...
On which exchange is INVA stock listed?
Innoviva (INVA) is associated with NASDAQ, United States, Biopharma.
What is Diversified?
Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies.
Which conditions is Innoviva targeting with Diversified?
Innoviva is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Innoviva describe recent progress with Diversified?
U.S. commercial availability of NUZOLVENCE in the second half of 2026.
What is Biopharmaceutical?
Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies.